{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:34:36Z","timestamp":1784187276481,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40263-025-01192-6","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T12:00:33Z","timestamp":1749038433000},"page":"779-793","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Subclinical Augmentation in Relation to Previous Dopaminergic Treatment in Patients with Restless Legs Syndrome: A Post Hoc Analysis of Two Randomized, Placebo-Controlled, Crossover Trials"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1083-9654","authenticated-orcid":false,"given":"Diego","family":"Garcia-Borreguero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Anguizola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Carvallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Garcia Arag\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Moncada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Ferr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"1192_CR1","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.sleep.2013.05.016","volume":"14","author":"D Garcia-Borreguero","year":"2013","unstructured":"Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Hogl B, et al. The long-term treatment of restless legs syndrome\/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14:675\u201384.","journal-title":"Sleep Med"},{"key":"1192_CR2","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/j.1468-1331.2012.03853.x","volume":"19","author":"D Garcia-Borreguero","year":"2012","unstructured":"Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, O\u2019Keeffe S, Trenkwalder C, Hogl B, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol. 2012;19:1385\u201396.","journal-title":"Eur J Neurol"},{"key":"1192_CR3","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.sleep.2006.09.009","volume":"8","author":"D Garcia-Borreguero","year":"2007","unstructured":"Garcia-Borreguero D, Grunstein R, Sridhar G, Dreykluft T, Montagna P, Dom R, et al. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med. 2007;8:742\u201352.","journal-title":"Sleep Med"},{"key":"1192_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/mds.24889","volume":"27","author":"D Garcia-Borreguero","year":"2012","unstructured":"Garcia-Borreguero D, Hogl B, Ferini-Strambi L, Winkelman J, Hill-Zabala C, Asgharian A, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord. 2012;27:277\u201383.","journal-title":"Mov Disord"},{"key":"1192_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.sleep.2010.12.007","volume":"12","author":"B H\u00f6gl","year":"2011","unstructured":"H\u00f6gl B, Garcia-Borreguero D, Trenkwalder C, Ferini-Strambi L, Hening W, Poewe W, et al. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med. 2011;12:351\u201360.","journal-title":"Sleep Med"},{"key":"1192_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.sleep.2011.09.016","volume":"13","author":"H Benes","year":"2012","unstructured":"Benes H, Garcia-Borreguero D, Ferini-Strambi L, Schollmayer E, Fichtner A, Kohnen R. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med. 2012;13:589\u201397.","journal-title":"Sleep Med"},{"key":"1192_CR7","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.sleep.2007.03.022","volume":"8","author":"D Garcia-Borreguero","year":"2007","unstructured":"Garcia-Borreguero D, Allen RP, Kohnen R, H\u00f6gl B, Trenkwalder C, Oertel W, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med. 2007;8:520\u201330.","journal-title":"Sleep Med"},{"key":"1192_CR8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00415-009-5299-8","volume":"257","author":"B H\u00f6gl","year":"2010","unstructured":"H\u00f6gl B, Garcia-Borreguero D, Kohnen R, Ferini-Strambi L, Hadjigeorgiou G, Hornyak M, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol. 2010;257:230\u20137.","journal-title":"J Neurol"},{"key":"1192_CR9","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.sleep.2010.08.001","volume":"11","author":"D Garcia-Borreguero","year":"2010","unstructured":"Garcia-Borreguero D, Allen R, Kohnen R, Benes H, Winkelman J, Hogl B, et al. Loss of response during long-term treatment of restless legs syndrome: guidelines approved by the International Restless Legs Syndrome Study Group for use in clinical trials. Sleep Med. 2010;11:956\u20137.","journal-title":"Sleep Med"},{"key":"1192_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.sleep.2016.01.017","volume":"21","author":"D Garcia-Borreguero","year":"2016","unstructured":"Garcia-Borreguero D, Silber MH, Winkelman JW, Hogl B, Bainbridge J, Buchfuhrer M, et al. Guidelines for the first-line treatment of restless legs syndrome\/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1\u201311.","journal-title":"Sleep Med"},{"key":"1192_CR11","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.sleep.2012.08.004","volume":"13","author":"MC Lipford","year":"2012","unstructured":"Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med. 2012;13:1280\u20135.","journal-title":"Sleep Med"},{"key":"1192_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.sleep.2010.11.002","volume":"12","author":"N Silver","year":"2011","unstructured":"Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011;12:440\u20134.","journal-title":"Sleep Med"},{"key":"1192_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.sleep.2018.11.025","volume":"55","author":"D Garcia-Borreguero","year":"2019","unstructured":"Garcia-Borreguero D, Cano-Pumarega I, Garcia Malo C, Cruz Velarde JA, Granizo JJ, Wanner V. Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment. Sleep Med. 2019;55:74\u201380.","journal-title":"Sleep Med"},{"key":"1192_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1073858418791763","volume":"25","author":"S Ferre","year":"2019","unstructured":"Ferre S, Garcia-Borreguero D, Allen RP, Earley CJ. New insights into the neurobiology of restless legs syndrome. Neuroscientist. 2019;25:113\u201325.","journal-title":"Neuroscientist"},{"key":"1192_CR15","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1002\/mds.28668","volume":"36","author":"D Garcia-Borreguero","year":"2021","unstructured":"Garcia-Borreguero D, Garcia-Malo C, Granizo JJ, Ferre S. A randomized, placebo-controlled crossover study with dipyridamole for restless legs syndrome. Mov Disord. 2021;36:2387\u201392.","journal-title":"Mov Disord"},{"key":"1192_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40263-023-01055-y","volume":"38","author":"D Garcia-Borreguero","year":"2024","unstructured":"Garcia-Borreguero D, Aragon AG, Moncada B, Romero S, Granizo JJ, Quintas S, et al. Treatment of sleep, motor and sensory symptoms with the orexin antagonist suvorexant in adults with idiopathic restless legs syndrome: a randomized double-blind crossover proof-of-concept study. CNS Drugs. 2024;38:45\u201354.","journal-title":"CNS Drugs"},{"key":"1192_CR17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.sleep.2014.03.025","volume":"15","author":"RP Allen","year":"2014","unstructured":"Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndrome\/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria\u2014History, rationale, description, and significance. Sleep Med. 2014;15:860\u201373.","journal-title":"Sleep Med"},{"key":"1192_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1389-9457(02)00258-7","volume":"4","author":"AS Walters","year":"2003","unstructured":"Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4:121\u201332.","journal-title":"Sleep Med"},{"key":"1192_CR19","unstructured":"Guy W, National Institute of Mental Health (U.S.). Psychopharmacology Research Branch., Early Clinical Drug Evaluation Program. ECDEU Assessment Manual for Psychopharmacology. Rev. ed. Rockville, MD.: U. S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976."},{"key":"1192_CR20","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.5665\/sleep.2820","volume":"36","author":"D Garcia-Borreguero","year":"2013","unstructured":"Garcia-Borreguero D, Kohnen R, Boothby L, Tzonova D, Larrosa O, Dunkl E. Validation of the multiple suggested immobilization test: a test for the assessment of severity of restless legs syndrome (Willis-Ekbom Disease). Sleep. 2013;36:1101\u20139.","journal-title":"Sleep"},{"key":"1192_CR21","unstructured":"American Academy of Sleep Medicine. AASM Manual for the Scoring of Sleep and Associated Events v2.62020."},{"key":"1192_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5664\/jcsm.5396","volume":"12","author":"WG Ondo","year":"2016","unstructured":"Ondo WG, Grieger F, Moran K, Kohnen R, Roth T. Post hoc analysis of data from two clinical trials evaluating the minimal clinically important change in international restless legs syndrome sum score in patients with restless legs syndrome (Willis-Ekbom Disease). J Clin Sleep Med. 2016;12:63\u201370.","journal-title":"J Clin Sleep Med"},{"key":"1192_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/archneurol.2009.294","volume":"67","author":"CA Rabinak","year":"2010","unstructured":"Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67:58\u201363.","journal-title":"Arch Neurol"},{"key":"1192_CR24","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/brain\/awm244","volume":"131","author":"S Fulda","year":"2008","unstructured":"Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain. 2008;131:902\u201317.","journal-title":"Brain"},{"key":"1192_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.sleep.2003.07.005","volume":"5","author":"JW Winkelman","year":"2004","unstructured":"Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004;5:9\u201314.","journal-title":"Sleep Med"},{"key":"1192_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.sleep.2011.03.003","volume":"12","author":"RP Allen","year":"2011","unstructured":"Allen RP, Ondo WG, Ball E, Calloway MO, Manjunath R, Higbie RL, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med. 2011;12:431\u20139.","journal-title":"Sleep Med"},{"key":"1192_CR27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.sleep.2008.09.007","volume":"10","author":"B Frauscher","year":"2009","unstructured":"Frauscher B, Gschliesser V, Brandauer E, El-Demerdash E, Kaneider M, Rucker L, et al. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels. Sleep Med. 2009;10:611\u20135.","journal-title":"Sleep Med"},{"key":"1192_CR28","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.sleep.2015.05.028","volume":"16","author":"T Mitterling","year":"2015","unstructured":"Mitterling T, Heidbreder A, Stefani A, Fritz J, Ulmer H, Poewe W, et al. Natural course of restless legs syndrome\/Willis-Ekbom disease: long-term observation of a large clinical cohort. Sleep Med. 2015;16:1252\u20138.","journal-title":"Sleep Med"},{"key":"1192_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsad273","author":"S Ferre","year":"2024","unstructured":"Ferre S, Winkelman JW, Garcia-Borreguero D, Belcher AM, Chang JH, Earley CJ. Restless legs syndrome, neuroleptic-induced akathisia, and opioid-withdrawal restlessness: shared neuronal mechanisms? Sleep. 2024. https:\/\/doi.org\/10.1093\/sleep\/zsad273.","journal-title":"Sleep"},{"key":"1192_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/caff.2019.0001","volume":"9","author":"S Ferre","year":"2019","unstructured":"Ferre S. The adenosine hypothesis of restless legs syndrome. J Caffeine Adenosine Res. 2019;9:1\u20133.","journal-title":"J Caffeine Adenosine Res."},{"key":"1192_CR31","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ana.25104","volume":"82","author":"G Yepes","year":"2017","unstructured":"Yepes G, Guitart X, Rea W, Newman AH, Allen RP, Earley CJ, et al. Targeting hypersensitive corticostriatal terminals in restless legs syndrome. Ann Neurol. 2017;82:951\u201360.","journal-title":"Ann Neurol"},{"key":"1192_CR32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.tips.2023.05.003","volume":"44","author":"S Ferre","year":"2023","unstructured":"Ferre S, Kofalvi A, Ciruela F, Justinova Z, Pistis M. Targeting corticostriatal transmission for the treatment of cannabinoid use disorder. Trends Pharmacol Sci. 2023;44:495\u2013506.","journal-title":"Trends Pharmacol Sci"},{"key":"1192_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0304-3940(96)12577-5","volume":"208","author":"S Ferre","year":"1996","unstructured":"Ferre S, Popoli P, Tinner-Staines B, Fuxe K. Adenosine A1 receptor-dopamine D1 receptor interaction in the rat limbic system: modulation of dopamine D1 receptor antagonist binding sites. Neurosci Lett. 1996;208:109\u201312.","journal-title":"Neurosci Lett"},{"key":"1192_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109329","volume":"223","author":"S Ferre","year":"2023","unstructured":"Ferre S, Sarasola LI, Quiroz C, Ciruela F. Presynaptic adenosine receptor heteromers as key modulators of glutamatergic and dopaminergic neurotransmission in the striatum. Neuropharmacology. 2023;223: 109329.","journal-title":"Neuropharmacology"},{"key":"1192_CR35","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1523\/JNEUROSCI.1548-21.2021","volume":"42","author":"BM Roberts","year":"2022","unstructured":"Roberts BM, Lambert E, Livesey JA, Wu Z, Li Y, Cragg SJ. Dopamine Release in nucleus accumbens is under tonic inhibition by adenosine A(1) receptors regulated by astrocytic ENT1 and dysregulated by ethanol. J Neurosci. 2022;42:1738\u201351.","journal-title":"J Neurosci"},{"key":"1192_CR36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jsmc.2021.02.012","volume":"16","author":"S Ferre","year":"2021","unstructured":"Ferre S, Guitart X, Quiroz C, Rea W, Garcia-Malo C, Garcia-Borreguero D, et al. Akathisia and restless legs syndrome: solving the dopaminergic paradox. Sleep Med Clin. 2021;16:249\u201367.","journal-title":"Sleep Med Clin"},{"key":"1192_CR37","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1073\/pnas.94.7.3363","volume":"94","author":"R Bordet","year":"1997","unstructured":"Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci U S A. 1997;94:3363\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1192_CR38","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.neuropharm.2018.06.024","volume":"138","author":"K Lanza","year":"2018","unstructured":"Lanza K, Meadows SM, Chambers NE, Nuss E, Deak MM, Ferr\u00e9 S, et al. Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: Implications for L-DOPA-induced dyskinesia. Neuropharmacology. 2018;138:304\u201314.","journal-title":"Neuropharmacology"},{"key":"1192_CR39","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/s41467-018-03889-3","volume":"9","author":"YJ Luo","year":"2018","unstructured":"Luo YJ, Li YD, Wang L, Yang SR, Yuan XS, Wang J, et al. Nucleus accumbens controls wakefulness by a subpopulation of neurons expressing dopamine D(1) receptors. Nat Commun. 2018;9:1576.","journal-title":"Nat Commun"},{"key":"1192_CR40","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1136\/practneurol-2017-001762","volume":"17","author":"S Wijemanne","year":"2017","unstructured":"Wijemanne S, Ondo W. Restless legs syndrome: clinical features, diagnosis and a practical approach to management. Pract Neurol. 2017;17:444\u201352.","journal-title":"Pract Neurol"},{"key":"1192_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5664\/jcsm.11390","volume":"21","author":"JW Winkelman","year":"2024","unstructured":"Winkelman JW, Berkowski JA, DelRosso LM, Koo BB, Scharf MT, Sharon D, et al. Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2024;21:137\u201352.","journal-title":"J Clin Sleep Med"},{"key":"1192_CR42","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.mayocp.2020.12.026","volume":"96","author":"MH Silber","year":"2021","unstructured":"Silber MH, Buchfuhrer MJ, Earley CJ, Koo BB, Manconi M, Winkelman JW, et al. The management of restless legs syndrome: an updated algorithm. Mayo Clin Proc. 2021;96:1921\u201337.","journal-title":"Mayo Clin Proc"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01192-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01192-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01192-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:47:06Z","timestamp":1757180826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01192-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1192"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01192-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"6 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the work undertaken for this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Diego Garcia-Borreguero has performed consulting work for Emalex Biosciences, Synendos Therapeutics and PsychoGenics Inc. David Anguizola has nothing to declare. Catalina Carballo has nothing to declare. Alba Garcia Arag\u00f3n has nothing to declare. Alejandro Lopez reports no disclosures relevant to the manuscript. Brian Moncada has nothing to declare. Sergi Ferr\u00e9\u2019s work is supported by the intramural funds of the National Institute on Drug Abuse.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable for the present study as this study does not involve new patients.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data generated during the course of this study are available upon reasonable request. The study protocol can be viewed by contacting the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"D.G.B. and S.F. conceived and designed the analysis; D.G.B., D.A., C.C., A.L.,\u00a0A.G.L., B.M. and S.F. collected and analysed the data. Statistical analysis was\u00a0completed by D.G.B. All authors contributed to the analysis of data and the writing of the paper, approved the current manuscript and accepted its submission to CNS Drugs. All authors have read and approve the final submitted manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}